HOME >> BIOLOGY >> NEWS
ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 11, 2007). ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a report in the prestigious Nature publication Leukemia confirming the positive clinical activity of the company's lead compound, Ceflatonin against Gleevec-resistant, chronic myeloid leukemia (CML) associated with the T315I Bcr-Abl mutation.

The T315I mutation is known to confer resistance to both Gleevec (imatinib mesylate) and second-generation tyrosine kinase inhibitors (dasatinib and nilotinib). Recent publications indicate that the incidence of T315I-associated resistance is increasing and confirm that this mutation is likely to become the prevalent mutation in those who fail tyrosine kinase inhibitor therapy.

The publication by Dr. Laurence Legros of the Hpital Archet, Nice, France and colleagues describes the treatment with Ceflatonin (homoharringtonine, HHT) of a Gleevec-resistant, chronic-phase CML patient with the T315I Bcr-Abl mutation. The authors report that the patient experienced a 50 percent reduction of T315I Bcr-Abl levels within 2.5 months of treatment initiation, and the complete disappearance of the mutation within 5.5 months of treatment. Complete hematological response (CHR) was achieved after three cycles of therapy.

Based on the clinical results, the authors believe that the rapid and complete disappearance of the T315I mutation might suggest a particular sensitivity of this mutation to HHT. The authors conclude that HHT "may provide an alternative therapeutic treatment option for CML patients with the T315I mutation, for whom therapies have been previously lacking."

The authors also noted some hematologic toxicities (neutropenia, thrombocytopenia and anemia), but confirmed that the toxicity of HHT was "easy to manage".

"We are delighted with this publication that reinforces our belief in the potential of Ceflatonin to treat patient
'"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
11-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... Ky. (PRWEB) , ... August 06, 2020 , ... ... selected to participate in the prestigious National STEM Scholar Program, a unique professional ... network building, and project support for middle school science teachers nationwide. , Created ...
(Date:7/22/2020)... (PRWEB) , ... July 21, 2020 , ... ... digital transformation and innovation in technology and compliance, announces a new solution to ... companies must ensure every layer of their technology stack complies with FDA and ...
(Date:7/4/2020)... ... July 03, 2020 , ... ... earn outstanding recognition and multiple awards for not only the products and treatments ... SoME® Skincare and Vivace® Microneedle RF. All the brands built by ABM have ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., ... and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson ...
(Date:7/7/2020)... ... 2020 , ... Bio-IT World has announced the winners of ... University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were ... outstanding examples of how technology innovations and strategic initiatives can be powerful forces ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... procured purchasing contracts to its membership, recently named BioFit Engineered Products ... the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts at ...
(Date:6/28/2020)... , ... June 25, 2020 , ... The Indoor Lab, ... of Safe Space™ for businesses of all types to ensure cleanliness, distancing and occupancy ... , A Safe Space™ enabled business will provide a health performance index system ...
Breaking Biology Technology:
Cached News: